Aftab D T, Ballas L M, Loomis C R, Hait W N
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510.
Mol Pharmacol. 1991 Nov;40(5):798-805.
Phenothiazines are known to inhibit the activity of protein kinase C. To identify structural features that determine inhibitory activity against the enzyme, we utilized a semiautomated assay [Anal. Biochem. 187:84-88 (1990)] to compare the potency of greater than 50 phenothiazines and related compounds. Potency was decreased by trifluoro substitution at position 2 on the phenothiazine nucleus and increased by quinoid structures on the nucleus. An alkyl bridge of at least three carbons connecting the terminal amine to the nucleus was required for activity. Primary amines and unsubstituted piperazines were the most potent amino side chains. We selected 7,8-dihydroxychlorpromazine (DHCP) (IC50 = 8.3 microM) and 2-chloro-9-(3-[1-piperazinyl]propylidene)thioxanthene (N751) (IC50 = 14 microM) for further study because of their potency and distinct structural features. Under standard (vesicle) assay conditions, DHCP was noncompetitive with respect to phosphatidylserine and a mixed-type inhibitor with respect to ATP. N751 was competitive with respect to phosphatidylserine and noncompetitive with respect to ATP. Using the mixed micelle assay, DHCP was a competitive inhibitor with respect to both phosphatidylserine and ATP. DHCP was selective for protein kinase C compared with cAMP-dependent protein kinase, calmodulin-dependent protein kinase type II, and casein kinase. N751 was more potent against protein kinase C compared with cAMP-dependent protein kinase and casein kinase but less potent against protein kinase C compared with calmodulin-dependent protein kinase type II. DHCP was analyzed for its ability to inhibit different isoenzymes of protein kinase C, and no significant isozyme selectivity was detected. These data provide important information for the rational design of more potent and selective inhibitors of protein kinase C.
已知吩噻嗪可抑制蛋白激酶C的活性。为了确定决定对该酶抑制活性的结构特征,我们利用一种半自动检测方法[《分析生物化学》187:84 - 88(1990)]来比较50多种吩噻嗪及相关化合物的效力。吩噻嗪核上2位的三氟取代会降低效力,而核上的醌型结构会增加效力。连接末端胺与核的烷基桥至少需要三个碳原子才能发挥活性。伯胺和未取代的哌嗪是最有效的氨基侧链。由于7,8 - 二羟基氯丙嗪(DHCP)(IC50 = 8.3 microM)和2 - 氯 - 9 -(3 - [1 - 哌嗪基]亚丙基)噻吨(N751)(IC50 = 14 microM)具有效力且结构特征独特,我们选择它们进行进一步研究。在标准(囊泡)检测条件下,DHCP对磷脂酰丝氨酸是非竞争性的,对ATP是混合型抑制剂。N751对磷脂酰丝氨酸是竞争性的,对ATP是非竞争性的。使用混合胶束检测法,DHCP对磷脂酰丝氨酸和ATP都是竞争性抑制剂。与环磷酸腺苷依赖性蛋白激酶、钙调蛋白依赖性蛋白激酶II型和酪蛋白激酶相比,DHCP对蛋白激酶C具有选择性。与环磷酸腺苷依赖性蛋白激酶和酪蛋白激酶相比,N751对蛋白激酶C的效力更强,但与钙调蛋白依赖性蛋白激酶II型相比,对蛋白激酶C的效力较弱。对DHCP抑制蛋白激酶C不同同工酶的能力进行了分析,未检测到明显的同工酶选择性。这些数据为合理设计更有效、更具选择性的蛋白激酶C抑制剂提供了重要信息。